Announcement

Collapse
No announcement yet.

Virol Sin . A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Virol Sin . A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial


    Virol Sin


    . 2020 Jul 21.
    doi: 10.1007/s12250-020-00258-7. Online ahead of print.
    A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial


    Ke Hu 1 , Mengmei Wang 2 , Yang Zhao 2 , Yunting Zhang 2 , Tao Wang 2 , Zhishui Zheng 2 , Xiaochen Li 2 , Shaolin Zeng 2 , Dong Zhao 2 , Honglin Li 3 , Ke Xu 4 , Ke Lan 5 6



    Affiliations

    Abstract

    We recently reported that inhibitors against human dihydroorotate dehydrogenase (DHODH) have broad-spectrum antiviral activities including their inhibitory efficacies on SARS-CoV-2 replication in infected cells. However, there are limited data from clinical studies to prove the application of DHODH inhibitors in Coronavirus disease 2019 (COVID-19) patients. In the present study, we evaluated Leflunomide, an approved DHODH inhibitor widely used as a modest immune regulator to treat autoimmune diseases, in treating COVID-19 disease with a small-scale of patients. Cases of 10 laboratory-confirmed COVID-19 patients of moderate type with obvious opacity in the lung were included. Five of the patients were treated with Leflunomide, and another five were treated as blank controls without a placebo. All the patients accepted standard supportive treatment for COVID-19. The patients given Leflunomide had a shorter viral shedding time (median of 5 days) than the controls (median of 11 days, P = 0.046). The patients given Leflunomide also showed a significant reduction in C-reactive protein levels, indicating that immunopathological inflammation was well controlled. No obvious adverse effects were observed in Leflunomide-treated patients, and they all discharged from the hospital faster than controls. This preliminary study on a small-scale compassionate use of Leflunomide provides clues for further understanding of Leflunomide as a potential antiviral drug against COVID-19.

    Keywords: Coronavirus disease 2019 (COVID-19); DHODH inhibitors; Inflammation; Leflunomide; Viral shedding time.

Working...
X